• Home
  • Articles
  • Global News
  • Interest
  • Health Tips
  • Write for Us
    • Contact Us
      • About
      • Privacy Policy

Browse Tag

Hypophosphatemia

Pharmacosmos' PHOSPHARE study program demonstrates a safety advantage of iron isomaltoside in relation to hypophosphatemia and other FGF23-mediated effects
March 26, 2019
Pharmaceutical News

Pharmacosmos’ PHOSPHARE study program demonstrates a safety advantage of iron isomaltoside

Pharmacosmos announces the first results of the PHOSPHARE study program in which iron isomaltoside was compared directly to ferric carboxymaltose in two identical randomized controlled trials. Iron isomaltoside 1000 and ferric carboxymaltose are intravenous iron preparations that can be administered in high doses to

More
Pharmacosmos' PHOSPHARE study program demonstrates a safety advantage of iron isomaltoside in relation to hypophosphatemia and other FGF23-mediated effects
Pharmaceutical News

Pharmacosmos’ PHOSPHARE study program demonstrates a safety advantage of iron isomaltoside

March 26, 2019

Pharmacosmos announces the first results of the PHOSPHARE study program in which iron isomaltoside was compared directly to ferric carboxymaltose

More
  • How To Overcome Common Breastfeeding Challenges
  • Can You Sue Your Doctor for Blindness Caused by Elmiron?
  • Experts advise European SME packaging firms to expand or seek acquisition prior to Pharmapack Europe
  • FIP advances sustainable health systems by providing new guidance for self-managing reflux symptoms
  • APAC overview: trends, challenges, and possibilities for growth in the MarTech sector

© 2010-2022 PharmaMirror.com - All Rights Reserved.

  • Home
  • Articles
  • Global News
  • Interest
  • Health Tips
  • Write for Us
  • Home
  • Articles
  • Global News
  • Interest
  • Health Tips
  • Write for Us
    • Contact Us
      • About
      • Privacy Policy
Go toTop